GRFS

Business Context and Reporting Period

Company: Grifols, S.A.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2012
Accounting Basis: International Financial Reporting Standards (IFRS)
Business Overview: Grifols is a vertically integrated global producer of plasma derivative products, diagnostics, and hospital supplies. The company operates four divisions: Bioscience (88.7% of revenue), Diagnostic, Hospital, and Raw Materials & Others. A defining event for the period was the full-year integration of the Talecris Biotherapeutics acquisition (completed June 1, 2011), which significantly expanded the company's U.S. footprint and plasma collection network to 150 centers.

Key Financial Metrics (Year Ended Dec 31, 2012)

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 46.0% to €2.62 billion. This was primarily driven by the inclusion of a full year of Talecris operations (2011 included only seven months) and organic growth in the U.S. and Canada, which now account for 63.3% of total sales.
• Profitability Surge: Operating profit more than doubled (up 136.7%) to €660.1 million, and net profit increased 408.4% to €255.4 million. The effective tax rate decreased to 34.2% from 37.2% in 2011.
• Expense Increases:
  • Cost of Sales: Increased 33.4% to €1.29 billion, aligned with higher manufacturing volumes.
  • R&D: Increased 39.3% to €124.4 million due to expanded clinical trials.
  • SG&A: Increased 18.7% to €545.1 million, though as a percentage of sales, it decreased from 25.6% to 20.8%.
  • Finance Costs: Increased 41.7% to €284.1 million, reflecting a full year of interest on debt incurred for the Talecris acquisition.
• Working Capital Improvements: Days Sales Outstanding (DSO) improved to 52 days from 65 days in 2011, driven by a shift in sales mix toward countries with shorter payment periods and a government payment plan in Spain. Inventory turnover days decreased to 281 from 319.

Guidance, Outlook, and Risks

Outlook and Capital Plan

Management expects global sales of plasma derivative products to grow 6% to 8% annually over the long term. The company is undertaking a capital expenditure plan of approximately €500 million from 2012 through 2015 to expand manufacturing capacity (targeting >12.5 million liters/year by 2015) and improve plasma collection centers. Liquidity is expected to be sufficient to fund operations and capital expenditures for at least the next 12 months via operating cash flows and existing credit facilities.

Key Risks and Contingencies

• Indebtedness: The company carries significant debt (€2.4 billion net financial debt) from the Talecris acquisition. High leverage restricts flexibility and increases vulnerability to economic downturns or interest rate fluctuations.
• Plasma Supply: Revenue growth is heavily dependent on access to U.S. source plasma. Constraints in the donor pool or regulatory issues could limit production.
• Regulatory & Reimbursement: The company faces risks from the U.S. 2010 Healthcare Reform Law (increased Medicaid rebates, Medicare Part D discounts) and price controls in European markets. Compliance with cGMP regulations is critical; failures could lead to facility shutdowns.
• Product Liability & Safety: Risks include contamination of plasma, adverse side effects, and product liability claims. The company self-insures the first €10 million of product liability claims.
• Concentration Risk: IVIG products accounted for approximately 50% of Bioscience division sales in 2012. Loss of market share or pricing pressure in this segment would materially impact results.

Investor Verification Checklist

• Debt Service Coverage: Verify the company's ability to service €2.4 billion in net debt given the high interest expense (€284 million) and reliance on operating cash flow.
• Plasma Collection Volumes: Confirm the 5.8 million liters collected in 2012 and assess the feasibility of meeting future demand without supply constraints.
• U.S. Market Exposure: Analyze the impact of U.S. reimbursement changes (Medicare/Medicaid) on the 63.3% of revenue derived from North America.
• Capital Expenditure Execution: Monitor the progress of the €500 million investment plan (2012-2015) and the timeline for new facility approvals (Clayton and Parets).
• Receivables Quality: Review the aging of receivables in Southern Europe (Spain, Italy, Portugal, Greece), where payment delays are common, despite the overall improvement in DSO.